|
Market Closed -
Nasdaq Stockholm
12:00:00 2026-10-23 pm EDT
|
5-day change | 1st Jan Change | ||
| 1.928 SEK | -2.72% |
|
-4.55% | -2.13% |
| Oct. 20 | Irlab research behind linepemat published in journal | FW |
| Oct. 20 | IRLAB Therapeutics AB Announces Publication Of Preclinical Research Underpinning Linepemat In Peer-Reviewed Journal | CI |
| Market Cap | 287M 28.88M 25.79M 23.83M 21.59M 40.4M 2.74B 41.06M 114M 1.44B 108M 106M 4.53B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 287M 28.88M 25.79M 23.83M 21.59M 40.4M 2.74B 41.06M 114M 1.44B 108M 106M 4.53B | EV / Sales 2026 * |
2.83x | EV / Sales 2027 * | 2x |
| Free-Float |
83.4% | Yield 2026 * |
-
| Yield 2027 * | - |
Nasdaq StockholmSEK
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| IRLAB A | Delayed | |
Deutsche Boerse AG
| 6IRA | Delayed | |
|
OTC Markets
| IRLAF | Delayed |
| 1 day | -2.72% | ||
| 1 week | -4.55% | ||
| Current month | +5.59% | ||
| 1 month | +7.59% | ||
| 3 months | +51.33% | ||
| 6 months | +30.98% | ||
| Current year | -2.13% |
| 1 week | 1.86 |  | 2.09 |
| 1 month | 1.7 | | 2.09 |
| Current year | 1.17 | | 2.14 |
| 1 year | 1.17 | | 2.78 |
| 3 years | 1.17 | | 20.2 |
| 5 years | 1.17 | | 51.5 |
| 10 years | 1.17 | | 110 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 2024-07-31 | |
Susanna Waters
PRN | Corporate Officer/Principal | 60 | 2012-12-31 |
Clas Sonesson
CTO | Chief Tech/Sci/R&D Officer | 65 | 2015-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Rein Piir
BRD | Director/Board Member | 68 | 2015-12-31 |
| Chairman | 73 | 2020-05-06 | |
Veronica Wallin
BRD | Director/Board Member | 40 | 2022-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/1/26 | Buy | Chairman | 31,000 | 38.8588% | ||
| 7/1/26 | Buy | Chief Technology Officer | 4,016,742 | - | ||
| 7/1/26 | Buy | Chief Executive Officer | 183,858 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.72% | -4.55% | -21.63% | -71.98% | 28.88M | |
| -2.54% | +1.31% | +55.10% | +120.84% | 1,135B | |
| -1.42% | +3.23% | +37.07% | +74.26% | 636B | |
| +0.16% | +0.08% | +25.14% | +97.36% | 505B | |
| -0.31% | +3.09% | +43.92% | +64.55% | 378B | |
| -1.34% | -0.47% | +66.63% | +40.56% | 358B | |
| -0.68% | +2.65% | +22.46% | +51.48% | 295B | |
| -1.20% | +3.04% | +2.62% | +26.97% | 266B | |
| -1.79% | +1.57% | +49.97% | +60.87% | 237B | |
| -0.73% | -0.10% | +29.24% | +101.19% | 193B | |
| Average | -0.87% | +1.50% | +31.05% | +56.61% | 400.44B | |
| Weighted average by Cap. | -0.26% | +2.66% | +40.99% | +82.13% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 101M 10.19M 9.1M 8.41M 7.62M 14.26M 968M 14.49M 40.07M 507M 38.26M 37.44M 1.6B | 143M 14.42M 12.88M 11.9M 10.78M 20.18M 1.37B 20.51M 56.69M 717M 54.14M 52.98M 2.26B |
| Net income | -36.1M -3.64M -3.25M -3M -2.72M -5.09M -345M -5.17M -14.29M -181M -13.65M -13.36M -570M | 34.6M 3.49M 3.11M 2.88M 2.61M 4.87M 331M 4.96M 13.7M 173M 13.08M 12.8M 547M |
| Net Debt | - | - |
Employees
31
Sector
Pharmaceuticals
Calendar
Nov. 10
Earnings release - Q3 2026
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-23 | SEK 1.928 | -2.72% | 621,231 |
| 26-10-22 | SEK 1.982 | -4.48% | 638,431 |
| 26-10-21 | SEK 2.075 | +0.48% | 421,941 |
| 26-10-20 | SEK 2.065 | +4.19% | 404,197 |
| 26-10-19 | SEK 1.982 | -1.88% | 935,209 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- IRLAB A Stock
Select your edition
All financial news and data tailored to specific country editions
